GLP-1 receptor agonist used for type 2 diabetes (Ozempic), chronic weight management with cardiovascular risk reduction (Wegovy), and oral type 2 diabetes (Rybelsus).
By Novo NordiskUpdated 2026-05-25
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
Semaglutide overview
GLP-1 receptor agonist used for type 2 diabetes (Ozempic), chronic weight management with cardiovascular risk reduction (Wegovy), and oral type 2 diabetes (Rybelsus).
Semaglutide at a glance
Manufacturer
Novo Nordisk
FDA status
FDA-approved
Pivotal trials
STEP-1 (NEJM 2021, PMID 33567185) — 14.9% mean weight loss at 2.4 mg / 68 weeks
SELECT (NEJM 2023, PMID 37952131) — 20% MACE reduction in non-diabetic adults with overweight/obesity + CVD
FLOW (NEJM 2024, PMID 38785189) — 24% reduction in major kidney/CV events in T2D + CKD
SURPASS-2 (NEJM 2021, PMID 34170647) — head-to-head: tirzepatide ~47% greater weight loss vs semaglutide 1 mg